Overview (Program Summary)
9:00 a.m. to 10:00 a.m. - Session I (Shook, Hardy & Bacon L.L.P.)
10:00 a.m. to 10:30 a.m. - BREAK
10:30 a.m. to 11:30 a.m. - Session II (McCarter & English, LLP)
Session I — Current Antitrust Issues For Health, Biotech, and Pharmaceutical Companies
The DOJ, FTC, and many state AGs are all promising a dramatic expansion of antitrust enforcement, and legislation that would overhaul existing antitrust laws is before Congress. This session will discuss the possible impact of the current enforcement environment on health, biotech, and pharma companies. We will discuss recent cases and policy statements as well as where enforcers might go next.
Session II — Ensuring Pharmaceutical Company Compliance with Updated PhRMA and FDA Guidelines
The year 2021 saw revisions to the PhRMA Code as well as new FDA guidance regarding off-label promotion. In this program, speakers from McCarter and English and Endo Pharmaceuticals Inc. will discuss these updates and provide guidance on how pharmaceutical companies can navigate these changes and remain compliant.
Use the red Register button to RSVP. The Zoom link will be provided with your completed registration, and is also shown below.
Ryan Sandrock, Co-Chair, Antitrust, Shook, Hardy & Bacon L.L.P. (San Francisco)
Aileen M. Fair, Senior Corporate Counsel-Litigation & Government Investigations | Antitrust & Competition Law, Bristol Myers Squibb